Human and animal health vaccine and biotherapeutic developer Pegasus Biotech latest to join Emergence

Contract research organization Pegasus Biotech Inc. is the latest bioscience company to join Emergence, Canada’s Bioscience Business Incubator. Founded in 2019, Pegasus Biotech is currently developing vaccines and biotherapeutics for the human and animal health sector and joins a cohort of 58 clients currently in the incubator program. 

Pegasus Biotech is an agile biotech company that focuses on providing high quality vaccine and biotherapeutic development services to the human and animal health sector. They are also developing accurate and reliable analytical testing methods for the human and animal health industry.

Based in Charlottetown, PEI, their team is comprised of three senior scientists with a combined 50+ years of experience in the biotechnology industry and more than 30 years of management experience. Pegasus Biotech’s areas of expertise include cell culture/fermentation and purification process development, analytical assay development, human and veterinary biologic product development and regulatory submission, point-of-care and clinical diagnostic instrument and assay development, GLP/GMP lab quality standards and HSE. 

“Our hope is that by leveraging the assistance offered by Emergence, that Pegasus can accelerate its journey to becoming a top-tier biotechnology CRO,” said Dan Wilson, Director of Operations, Pegasus Biotech.

Emergence is a business incubator dedicated to assisting start-ups and growth-stage bioscience companies in efficiently bringing their products and services to market. As part of the Emergence program, Pegasus Biotech will have access to business incubation services including: 

Mentorship and advisory services: Emergence companies receive long-term expert advice from mentors, selected for their relevant experience, as well as services to fill in specific gaps in the company’s critical path.

Team Mentorship Program: The Critical Path Team Mentorship Program matches companies with skilled volunteer mentors to provide practical, day-to-day professional advice and business coaching. 

Access to networks and resources: Emergence companies have access to networks including funding agencies, regulatory bodies, future talent, public organizations, service providers, investors, potential partners, and bioscience cluster companies.

For more information on Emergence, visit

Posted in Uncategorized

Bioscience company uses technology as a platform for pain measurement

Emergence client BioTraceIT is a company that has developed a platform for detecting and monitoring pain in people and animals.

The company’s hardware device uses skin sensors to detect biosignals related to disease and pain. Software produced by the company gathers, receives, processes, transmits, and displays the data. The use of IT Analytics helps to understand what treatments are most effective and what groups of people or animals will benefit from a particular treatment.

Manufacturing of the devices is done in Ontario, and the research and development and technical support teams are located on PEI. Six people work on PEI now, and they are planning to add more employees on the Island in the near future.

“We are just starting our sales, which means if all goes well we will go from a small start-up to a much bigger company,” says Deborah Dullen, President and CEO of BioTraceIT™.

Read full story on BioTraceIT in the Employment Journey.

Posted in Uncategorized

Comfort builds confidence with Au Naturel Solutions

For breast cancer survivor Simonne Cormier, her road to recovery led to an innovative idea that would have a lasting impact.

Diagnosed suddenly in 2016she faced two significant challenges relating to her post-treatment circumstance: finding a breast prothesis made from natural materials and finding an appropriate means of attaching and securing the prothesis.

“After having had surgery, chemo and radiation, it was recommended to find a breast prosthesis that was made from all-natural materials, as your sensitive skin is breathing whatever material it is in contact with,” she said. “I searched specialty stores far and wide across Canada and the online marketplace. Unfortunately for me and any other patients, that product did not exist.”

That is, until now. In 2019, Simonne founded Au Naturel Solutions, a company specializing in the manufacturing of an all-natural breast prosthesis with an attachment system. In contrast to the existing synthetic polyester or silicone options, Au Naturel’s product is made from animal and plant-based fibers.

“Part of the problem with existing products, was the need to constantly adjust and re-adjust throughout the day. With the innovative attaching system, the prosthesis remains securely in place and the prosthesis itself can be adapted to fit the negative space from surgery, making it easier to align the shape and size of the other breast.”

Au Naturel Solutions is the latest company to join Emergence, Canada’s Bioscience Business Incubator run by the PEI BioAlliance, and serving 58 client companies in the Atlantic Region and across Canada. Simonne also received a $25,000 grant in 2019 from Innovation PEI’s Ignition Fund and is an active member of the Startup Zone.

“Emergence is working with Simonne to put the product into full production in 2021 and to develop a sales and marketing plan to make the product available across Canada, and wherever there is a need,” said Mark Redmond, Director, Incubation Services for Emergence.

Simonne’s innovative product includes a prosthesis comprised of a molded breast form with fiber fill to be placed within a bra cup to correct asymmetry, as well as an innovative system to keep the prosthesis securely in place. The all-natural materials were selected for their hypoallergenic and biodegradable properties, breathability, moisture wicking and durability.

“I chose this route to give others the option of an all-natural alternative, if that’s what they want. This exercise is about making people feel good, being comfortable and building confidence in themselves.”

October is Breast Cancer Awareness Month, dedicated to education and making a difference in the lives of those affected by the disease. With more than 26,000 Canadians diagnosed every year, it is the most common form of cancer.

“Imagine going through surgery, not knowing to what extent the removal of tissue will be. This happens to many individuals undergoing surgery following a breast cancer diagnosis. I want to give back to that community and aid in the healing of individuals who need a prosthesis for whatever reason.”

For more information on Au Naturel Solutions, contact Simonne at

Posted in Uncategorized

AffinityImmuno Inc. named as one of eight semi-finalists to present at the virtual BioInnovation Challenge pitch event

Emergence client AffinityImmuno Inc. has been named as one of eight semi-finalists to compete in the 10th annual BioInnovation Challenge (BIC), BioNova’s regional health and life sciences business competition, which will be held virtually on November 3rd and 4th during BioPort 2020.

BIC is one of the longest running business competitions in the region with over 50 companies having gone through the program since 2011. Many of the companies coming out of the program have gone on to raise millions to grow and scale. ABK BioMedical, the first place winner of BIC 2011, raised a record-setting $30M USD venture capital round in 2019.

Semi-finalists will receive significant training to be positioned for business growth, including sessions with expert pitch training coach Linda Plano, who has over ten years of experience mentoring entrepreneurs with start-ups in life sciences. This year’s winner will receive $25,000 in funding to develop their business idea as well as a package of support services and mentoring valued at more than $30,000.

Learn more about the eight (8) semi-finalists who will be pitching virtually on November 3rdduring BioPort 2020:

AffinityImmuno Inc. – PEI
Jonathan Zuccolo, Founder
AffinityImmuno Inc. has developed a novel serum test to meet the challenge of monitoring development of immunity to the ongoing SARS-CoV-2 pandemic. The virus neutralization test monitors vaccine responses, population spread of a virus, and length of immune response.

3D BioFibR – NS
Kevin Sullivan, CEO
3D BioFibR technology is a platform technology capable of creating a variety of high value biofibres. Its
collagen fibres have properties resembling the human body. In the lab, this material can be used to create a highly consistent scaffold for 3D tissue culture. In medicine, this material can be doped with antimicrobial agents and drugs to promote wound healing, producing a bandage that can seal a wound.

Clever Fruit Products – NS
Liam Tayler, President
Clever Fruit Products has developed proprietary fermentation technologies which create a product that improves the bioavailability of fruit polyphenols. The company is seeking to maximize the nutritional potential of Nova Scotian wild blueberry, and aid in people’s access to their many health benefits.

eNable Analytics – NB
Alex Roberts
eNable Analytics is a data-centric machine learning company that has developed an innovative platform that turns assistive devices (canes, walkers, and rollators) into remote monitoring tools. Combined with innovative machine learning-based analyses, they provide regular and proactive insights about the physical and behavioural health of users.

Greenlight Analytical – NS
Dr. James Wylde, President & CEO
Greenlight Analytical will be advancing their chemical analyzer, initially designed for safety and quality control of cannabis crops, to extend its capability to detect toxins in illicit narcotics. The portability and ease-of-use will allow the instrument to be used by first responders to identify the presence of toxins, such as fentanyl, in a medical emergency (overdose) and allow them to take appropriate safety measures to avoid contamination or exposure.

Parados Cerebral Solutions – NB
Pascal McCarthy, CEO
Parados is developing a mouth guard with sensors that will allow athletes to know whether they have sustained a head injury that is likely to lead to a concussion. Over time, an artificial intelligence system will be able to offer insights into the cumulative effects athletes face when they suffer repeated brain injuries.

Swiftsure Innovations – NF
Deanne McCarthy (RN), CEO & Founder
The Complete Care Endotracheal Tube (CCET), patent pending, is a novel endotracheal tube that will revolutionize oral care for mechanically ventilated patients. CCET is the first medical device that allows for large volume nasal and oral irrigation of patients on life support without risk of aspiration or tissue injury, while simultaneously limiting the production of aerosols.

Symbi Medical – NS
Cameron Sehl, CEO & Co-founder
Symbi is a cloud-based remote patient monitoring system for GI care. Symbi creates personalized care plans for each patient to follow in-between appointments and uses text messaging to monitor patients throughout each stage of their care and identify those who are at higher risk of health complications.

BIC 2020 is presented by BioNova in partnership with the Atlantic Canada Opportunities Agency, BioNB, Emergence, Gallagher Insurance, Cox & Palmer, Jennifer Cameron PR, and Bereskin & Parr.

BIC 2020 will take place over two days in November. The eight (8) semi-finalists will present to a panel of judges and the conference audience during BioPort’s virtual conference, on November 3rd. The top three presenters will then pitch virtually the following morning.  The winner will be announced at the close of BioPort 2020 on the afternoon of November 4th.

Posted in Uncategorized

Ahiflower oil receives Canadian novel foods approval

Emergence client Natures Crops International has announced that the Health Canada Food Directorate has approved Ahiflower® oil for use in foods in Canada. This is according to a letter of no objection dated July 17th, 2020 received by Natures Crops International.

Greg Cumberford, VP Science & Regulatory, stated, “Natures Crops is delighted for Ahiflower oil, which is produced in Prince Edward Island at our dedicated refinery, to now be available in foods and beverage products widely in Canada. Ahiflower oil provides a unique balance of omega fatty acids and its clean taste and aroma make it ideal for brands seeking to improve omega-3 levels from a regenerative plant-based source.”

According to Health Canada’s Bureau of Nutritional Sciences, characterizing the work performed to assess Ahiflower oil’s safety, “Scientists at Health Canada with expertise in molecular biology, microbiology, toxicology, chemistry, and nutrition conducted a thorough analysis of the data and the protocols provided by the applicant to ensure the validity of the results. To ensure that the Ahiflower® oil is safe for consumption, the scientists considered how the products were developed, their composition, whether they could be toxic or cause allergic reactions, and their dietary exposure in the Canadian population. Following this assessment, it was determined that the use of Ahiflower® oil is safe as an ingredient for use in foods and beverages at a level providing up to 375 mg stearidonic acid per serving of food.”

Ahiflower oil is the richest-available natural source of omega-3 stearidonic acid and omega-6 gamma linolenic acid in a dietary oil. Health Canada’s allowed limit translates to approximately 2 grams Ahiflower oil per serving in a wide range of foods including dairy and dairy analog beverages, vegetable and fruit juices, oils and dressings, sauces, baked goods, snack foods, soups, and soft candy.

Ahiflower oil is grown and manufactured exclusively by Natures Crops International. For more information, please visit

Posted in News

3 reasons Emergence companies should apply for the BioInnovation Challenge

Now in its tenth year, the BioInnovation Challenge (BIC) is a pitching competition for early-stage life sciences companies in Atlantic Canada. BIC was created by BioNova to help ease the transition from research to market and recognize the significant commercialization potential of the bioscience sector in Atlantic Canada.

Last year, three Emergence companies were semi-finalists in the BIC: AffinityImmuno and Fieldetect of Prince Edward Island, and Dr. A.K. Gordon of Nova Scotia. This year’s finalists will present at BioPort 2020 in November.

Here are three reasons you should consider applying:

1. Access to funding
The winner of the pitch competition will be awarded $25,000 in funding to help develop their business and a $30,000 advisory services package. Since its inception in 2011, BIC has provided more than $300K in grand prize package value to accelerate start-ups.

2. Pitch training and business development
BIC participants receive pitching and business training to help position their company for continued growth. BIC also connects finalists with investors, the media and industry influencers. Take advantage of the spotlight and kick-start your success.

3. Applying is easy
Deadline for applications is Friday, August 7, 2020. Email to receive a copy of the application.

Emergence is a proud supporter of BIC. For more information on the program, visit their website.

Posted in Clients, News

Auxly’s Subsidiary Dosecann Enters into Manufacturing and Distribution Agreement with dosist™, an Award-Winning Wellness Company

TORONTO, June 24, 2020 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”), a leading consumer packaged goods company in the derivative cannabis products market, is pleased to announce that its wholly-owned subsidiary Dosecann LD Inc. (“Dosecann”) has entered into an agreement with GSW Creative Corporation Canada Inc., doing business as dosist (“dosist”), to manufacture their proprietary wellness vape devices at Dosecann’s facility in Prince Edward Island.

Dosecann will utilize its production capabilities, capacity, and world-class expertise in cannabis derivative products to manufacture dosist’s innovative dose control solutions. dosist will also utilize Auxly’s well-established national distribution channels to bring its proprietary new innovations to Canadians nation-wide, including their newly engineered dose pen 100, their new range of high potency formulas for THC-forward experiences called thc-plus, and their new rechargeable dose pen system. To view the full press release, link here.

Posted in Clients, News

SP Nutraceuticals Launches First Avocado-based Supplement Metavo to Target Insulin Resistance, Support Healthy Metabolism

Metavo contains AvoB, a powerful bioactive discovered by Canadian scientists and  known to support healthy metabolism, blood sugar levels and weight in adults

SP Nutraceuticals (SP), as part of its mission to build healthy communities through plant-based nutrition backed by rigorous science, is proud to announce the launch of Metavo, a natural supplement that contains avocatin B (AvoB). AvoB is a powerful bioactive naturally found in avocados that helps maintain normal blood glucose (sugar) levels and supports healthy metabolism.

In collaboration with a team of nutritional scientists from the University of Guelph lead by renowned nutraceutical expert and researcher, Dr. Paul Spagnuolo, conducted extensive research and identified and isolated the new bioactive. AvoB can be used to maintain a healthy metabolism, blood sugar levels and weight in adults naturally, effectively and safely. It is particularly beneficial for those who are looking to manage blood sugar levels, those who are pre-diabetic, obese or overweight.

Continue reading

Posted in Clients, News

Join us in welcoming Robin Muzzerall, Facility Manager, CAT Victoria-PEI Plant

Robin Muzzerall, Facility Manager, CATC Victoria-Prince Edward Island Plant

The Emergence community welcomes Robin Muzzerall as she begins her new role as Facility Manager at the CAT Victoria-PEI Plant. As Facility Manager, Robin will oversee operations of the newly acquired facility in Victoria by the Sea. The recent acquisition of the 46,000 sq ft campus, which houses both aquatic and dry lab space, will triple the Canadian footprint for the Center for Aquaculture Technologies (CAT) and make it the largest aquaculture CRO in the world with BSL3 containment certification. Robin brings extensive skills to the position with more than 25 years of leadership experience in the Canadian Aquaculture Industry.  She will play a critical role in helping CAT scale its service-orientated activities and further enhance its global reputation while championing innovation within Aquaculture and Bioscience related industries. After sharing her passion for aquaculture across the country, she is thrilled to return home to the Maritimes to establish strong ties with the local community of Victoria and join the thriving bioscience sector on beautiful Prince Edward Island.

Robin’s bio:

Robin was introduced to the culture of lobster while completing her BSc. Biology at St. Mary’s University in Halifax. Following graduation, having an interest in growing livestock, Robin began her aquaculture career on the east coast. Early on this included supervising the wet lab and managing trials for Aqua Health Ltd., in PEI. Following that time Robin has spent more than 25 years as a hands-on manager in freshwater production of salmon and arctic char including responsibilities of broodstock management, egg, fry and smolt production for internal and external customers. She has worked on both coasts and in the north. Robin has also been an integral part of several facility projects including retrofits, new builds and commissioning of new systems.

Robin’s management experience and style is one that encourages growth and development of the skills of others to promote the success of the operation. Robin also sees the value of community engagement to promote the industry.

Robin returned to PEI to join CATC in May 2020, almost full circle to where she began her interest and career in aquaculture.

Connect with Robin on LinkedIN:

Follow news from Center for Aquaculture Technologies on LinkedIN:

Related story:

CATC acquires research facility

Posted in Careers, Clients, Leaders

Alpha Cognition Inc. announces granted EU patents and orphan drug designation for its Progranulin platform

Emergence client Alpha Cognition Inc. (ACI) [formerly Neurodyn Cognition], a clinical stage biotherapeutics company, announced today it has been granted two EU patents (EP2249861A1 and EP3009143A1) relating to the treatment of neurodegenerative diseases using progranulin.  Additionally, the FDA, has granted ACI Orphan Drug Designation for its progranulin product platform for the treatment of amyotrophic lateral sclerosis (ALS). Alpha Cognition operates its laboratory facilities in the Prince Edward Island Bioscience Cluster, Canada.

Alpha-602, progranulin, is a protein that has a potent ability to protect neurons that are under stress. In pre-clinical studies, ACI has demonstrated that progranulin can correct the cellular defects caused by the altered patterns of proteins in motor neurons.  ACI is developing a specific form of progranulin, called Alpha-602, for the treatment of ALS patients.

ACI’s growing list of granted patents now includes two more in Europe.  These patents relate to methods and compositions for the treatment of neurodegenerative diseases using progranulin, and methods of treatment of neurodegenerative diseases using effectors, or combinations of effectors, that modify progranulin expression.

The Orphan Drug Act (ODA) provides special incentives for the development of treatments for rare diseases, such as ALS. For a drug to qualify for orphan-drug designation both the drug and the disease must meet certain specified criteria.  In Q1 of 2020, the FDA granted orphan-drug designation to Alpha-602 for the treatment of ALS.  Alpha-602, is currently advancing through pre-clinical development and toxicology programs.

ACI’s Chief Scientific Officer, Dr. Denis Kay, stated, “These granted patents, together with the orphan-drug designation, mark significant milestones in the clinical development path of Alpha-602 for the treatment of ALS.”

For additional information about the Company and its research programs, visit the Company’s website at 

About Alpha Cognition Inc. – Alpha Cognition Inc. (ACI) is engaged in neurological disease research and has developed programs in Alzheimer’s Disease and amyotrophic lateral sclerosis (ALS).

  • Alpha-1062 is a patented new chemical entity that has shown efficacy in preclinical and recently completed human clinical trials. It is being developed as a new generation acetylcholine esterase inhibitor (AChEI) with minimal gastrointestinal side effects and new routes of administration. Alpha-1062’s active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition.
  • Alpha-602 (Progranulin) is a natural protein that is expressed in several cell types in the central nervous system and in peripheral tissues. Alpha-602 regulates cell survival and certain inflammatory processes. The protein plays a major role in regulating lysosomal function and microglial responses to disease. Its use in the treatment of ALS has been patented by ACI.

For additional information about this press release contact:

For additional information about the company contact:

Or write to:

Investor Relations
Alpha Cognition Inc.
439 Helmcken Street,
Vancouver, B.C. V6B 2E6

Posted in Clients